Does Rhode Island Medicaid Cover Wegovy or Zepbound?
Rhode Island (RI) GLP-1 access depends on three state-specific policy questions before it ever gets to pricing: does Rhode Island Medicaid cover weight-loss GLP-1s, has Rhode Island expanded Medicaid under the ACA, and does the state employee health plan cover them. Answering those first tells you whether you're likely working with insurance or planning for cash-pay.
Rhode Island Medicaid GLP-1 coverage: what the state's own documents say
Rhode Island Medicaid (fee-for-service and managed care plans) stopped covering Foundayo, Saxenda, Wegovy and Zepbound when prescribed solely for weight loss on October 1, 2026, under the enacted FY2027 budget (EOHHS provider memo dated August 5, 2026; EOHHS's FY2027 initiatives page, last updated October 7, 2026, shows no delay). Wegovy and Zepbound can still be covered with prior authorization for other FDA-approved indications named in a managed care plan's notice (cardiovascular risk reduction, MASH and obstructive sleep apnea), GLP-1s approved for type 2 diabetes remain covered, and requests for members under 21 are reviewed for medical necessity under EPSDT. We did not find a notice published after October 1 confirming implementation.
Checked October 12, 2026 against: eohhs.ri.gov, eohhs.ri.gov, point32health.org, webserver.rilegislature.gov.
Rhode Island state employee health plan: what the plan's own documents say
Not fully verified. The State's CVS Caremark formulary (October 2025) lists Wegovy, Saxenda, Qsymia and orlistat as preferred anti-obesity drugs and puts Zepbound on a formulary-removal list, and the Office of Employee Benefits' list of excluded drug categories omits weight-loss drugs, which points toward coverage. But the plan-level prescription document, prior-authorization criteria and copay tier were not found, and the BCBSRI medical booklet excludes 'Prescribed weight-loss drugs' while deferring pharmacy drugs to a separate Prescription Drug Plan document that was not located.
Checked September 20, 2026 against: employeebenefits.ri.gov, employeebenefits.ri.gov, employeebenefits.ri.gov.
Notable insurers active in Rhode Island (not independently verified): Blue Cross Blue Shield of Rhode Island, Tufts Health Plan, UnitedHealthcare.
Why GLP-1 coverage varies this much by state
Medicaid is a state-federal partnership, not a single national program. Each state Medicaid agency sets its own preferred drug list (PDL) and prior-authorization criteria within federal minimum requirements. Weight-loss drugs are not a federally mandated Medicaid benefit, so states choose independently whether to cover them - which is why only 10 of 50 states currently do (Rhode Island is not one of them).
State employee health plans are a useful bellwether. These plans cover hundreds of thousands of state workers and negotiate directly with pharmacy benefit managers, so their coverage decisions often signal where commercial insurers in that state are heading. North Carolina's State Health Plan, for example, ended coverage of weight-loss GLP-1s on April 1, 2024, after its board voted 4-3 to cut it citing the drugs' high cost - a case that other states and large employers have watched closely.
Medicaid expansion status shapes who even has coverage to begin with. States that haven't adopted ACA Medicaid expansion have narrower Medicaid eligibility overall, which - combined with the weight-loss GLP-1 exclusion most states apply regardless of expansion status - pushes a larger share of residents in those states toward commercial insurance, telehealth, or manufacturer self-pay as their only realistic path.
National reference pricing (same nationwide - your actual cost depends on your plan)
These prices are the same across all 50 states because manufacturer list prices, self-pay programs, and telehealth pricing don't vary by state - only insurance coverage and copay do, which is why the Rhode Island-specific policy facts above matter more than the table below for predicting your actual cost.
| Drug | Covered by insurance | Manufacturer self-pay | Telehealth | Cash retail |
|---|---|---|---|---|
| Wegovy 14.9% weight loss | $63 | $349 | $329 | $1,349 |
| Ozempic 11.6% weight loss | $63 | - | $399 | $1,028 |
| Wegovy (oral 25mg) 13.6% weight loss | $63 | $149 | $449 | $1,349 |
| Zepbound 22.5% weight loss | $88 | $299 | $499 | $1,059 |
| Mounjaro 20.9% weight loss | $88 | - | $499 | $1,069 |
| Saxenda 8.4% weight loss | $63 | - | $399 | $1,349 |
| Foundayo (orforglipron) 14.7% weight loss | $63 | $149 | - | $1,099 |
| CagriSema 20.4% weight loss | $88 | $599 | - | $1,499 |
Cheapest cash-pay GLP-1 paths for Rhode Island residents
Manufacturer direct prices (LillyDirect, NovoCare) are usually cheapest. Updated May 2026.
| Drug | Insurance | Mfr direct | Telehealth (brand) | Telehealth (compd) | Cash retail | Get it |
|---|---|---|---|---|---|---|
| Wegovy 14.9% weight loss | $63 | $349 | $329 | $249 cheapest | $1,349 | Get →ad |
| Ozempic 11.6% weight loss | $63 | - | $399 | $199 cheapest | $1,028 | Get →ad |
| Wegovy (oral 25mg) 13.6% weight loss | $63 | $149 cheapest | $449 | - | $1,349 | Get →ad |
| Zepbound 22.5% weight loss | $88 | $299 cheapest | $499 | $299 cheapest | $1,059 | Get →ad |
| Mounjaro 20.9% weight loss | $88 | - | $499 | $299 cheapest | $1,069 | Get →ad |
| Saxenda 8.4% weight loss | $63 | - | $399 cheapest | - | $1,349 | Get →ad |
| Foundayo (orforglipron) 14.7% weight loss | $63 | $149 cheapest | - | - | $1,099 | Get →ad |
Rhode Island carrier coverage details
National carriers active in Rhode Island (this list is not independently verified). Drill into each carrier's prior-auth requirements, formulary, and appeal playbook.
Frequently asked questions
Does Rhode Island Medicaid cover Wegovy or Zepbound for weight loss?
No - coverage ended October 1, 2026. Rhode Island Medicaid (fee-for-service and managed care plans) stopped covering Foundayo, Saxenda, Wegovy and Zepbound when prescribed solely for weight loss on October 1, 2026, under the enacted FY2027 budget (EOHHS provider memo dated August 5, 2026; EOHHS's FY2027 initiatives page, last updated October 7, 2026, shows no delay). Wegovy and Zepbound can still be covered with prior authorization for other FDA-approved indications named in a managed care plan's notice (cardiovascular risk reduction, MASH and obstructive sleep apnea), GLP-1s approved for type 2 diabetes remain covered, and requests for members under 21 are reviewed for medical necessity under EPSDT. We did not find a notice published after October 1 confirming implementation. This was checked against Rhode Island's own documents on October 12, 2026; coverage rules change often, so confirm with your plan before relying on it. Coverage for type 2 diabetes (Ozempic, Mounjaro) is a separate question. Medicare's GLP-1 Bridge, which started July 1, 2026, works separately from Medicaid and applies in every state.
Has Rhode Island expanded Medicaid under the ACA?
Yes - Rhode Island has adopted Medicaid expansion, which broadens who qualifies for Medicaid coverage generally, though it does not by itself guarantee GLP-1 weight-loss coverage (see above).
Does the Rhode Island state employee health plan cover Wegovy or Zepbound?
We could not verify this. Not fully verified. The State's CVS Caremark formulary (October 2025) lists Wegovy, Saxenda, Qsymia and orlistat as preferred anti-obesity drugs and puts Zepbound on a formulary-removal list, and the Office of Employee Benefits' list of excluded drug categories omits weight-loss drugs, which points toward coverage. But the plan-level prescription document, prior-authorization criteria and copay tier were not found, and the BCBSRI medical booklet excludes 'Prescribed weight-loss drugs' while deferring pharmacy drugs to a separate Prescription Drug Plan document that was not located. Check the current plan documents or ask the plan directly.